Physician

Madhu V Midathada, MD

According to 2025 Medicare claims, Madhu Midathada, MD (NPI: 1265511034) practices hematology/oncology in the Lincoln, NE market, with the plurality of this provider's patient population coming from Lancaster, NE. This provider's primary affiliated billing organization is NEBRASKA HEMATOLOGY-ONCOLOGY, PC (NPI: 1205915071; TIN: 911806105) and primary practice location at 68506-7548. Midathada is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287), Bryan Health Connect ACO, LLC (ACO ID: A4573), Caravan Health ACO 50 LLC (ACO ID: A5160), and Aledade 149 Regional MSSP (ACO ID: A5231), participating under the MSSP model.

Midathada's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 895 traditional Medicare patients, billed 294,657 HCPCS/CPT codes, and received $4,895,824 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,320 prescription claims across 249 beneficiaries totaling $3,453,359 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 41 claims. Open Payments data shows 21 records totaling $298,271. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,747,266 to $4,895,824. Similarly, Part D prescription costs have moved sharply higher in recent years, from $632,269 to $3,453,359. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	598	113,429	$1,747,266
2016	527	110,806	$1,527,535
2017	594	118,138	$1,976,502
2018	647	123,794	$2,488,732
2019	666	145,764	$2,021,255
2020	689	169,781	$2,617,933
2021	803	181,750	$3,383,265
2022	893	250,961	$4,232,195
2023	821	232,656	$3,774,835
2024	895	294,657	$4,895,824

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	136	720	$632,269
2016	134	943	$1,277,097
2017	153	1,012	$1,372,870
2018	195	1,131	$1,972,818
2019	184	1,051	$1,689,378
2020	170	1,005	$1,835,936
2021	213	1,149	$1,902,287
2022	219	1,064	$2,680,070
2023	220	1,086	$3,915,799
2024	249	1,320	$3,453,359

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$538
2016	N/R	12	$226
2017	N/R	44	$10,817
2018	N/R	46	$6,268
2019	N/R	11	$1,323
2020	N/R	12	$667
2021	N/R	N/R	N/R
2022	N/R	34	$1,250
2023	N/R	11	$8,685
2024	N/R	41	$1,184

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	411	828	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	376	528	$12
80053	Blood test, comprehensive group of blood chemicals	735	1,795	$10
36415	Insertion of needle into vein for collection of blood sample	663	1,485	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	770	2,094	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	37	994	$463,646
Kisqali	Ribociclib Succinate	32	875	$457,246
Revlimid	Lenalidomide	24	672	$419,409
Imbruvica	Ibrutinib	19	532	$290,810
Ibrance	Palbociclib	18	504	$268,255

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$883
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$3,755	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$294,516	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Madhu V. Midathada, MD?

Tedicare shows public-source Medicare data for Madhu V. Midathada, MD (NPI 1265511034), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Madhu V. Midathada, MD have ACO affiliation data?

Madhu V. Midathada, MD is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287), Bryan Health Connect ACO, LLC (MSSP, ACO ID A4573), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), and Aledade 149 Regional MSSP (MSSP, ACO ID A5231).

What billing organization is linked to Madhu V. Midathada, MD?

Madhu V. Midathada, MD is linked to NEBRASKA HEMATOLOGY-ONCOLOGY, PC (billing NPI 1205915071) in the available physician profile data.

Does Madhu V. Midathada, MD have Open Payments data?

Madhu V. Midathada, MD has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.